MHRA aligns Declaration of Helsinki with UK Clinical Trial Regulations: What manufacturers need to know

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published new guidance clarifying how the Declaration of Helsinki aligns with the amended Clinical Trials Regulations, which will come into force on 28 April 2026.

This update provides important clarification for sponsors and investigators—particularly manufacturers involved in clinical investigations—on how to balance international ethical principles with UK legal requirements.

Legal status and expectations

The guidance accompanies the amended Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended in 2025). It confirms that:

• Sponsors and investigators must consider all relevant guidance when conducting clinical trials

• Compliance with this guidance is necessary to maintain regulatory compliance

• Responsibility extends to any delegated parties involved in trial activities

For manufacturers: This reinforces the need for robust oversight of CROs and partners, ensuring alignment with both regulatory and ethical frameworks.

Declaration of Helsinki formally embedded

A key change is the explicit integration of the Declaration of Helsinki principles into UK law:

• Compliance is required with the principles, not a specific version

• These principles apply to all clinical trials, unless they conflict with UK regulations

Impact: Manufacturers must ensure that clinical strategies, protocols, and documentation reflect ethical principles such as patient protection, scientific validity, and transparency—even where not explicitly detailed in UK legislation.

Key areas of potential conflict

The MHRA highlights specific areas where tensions may arise between the Declaration and UK law:

1. Use of placebo

• The Declaration restricts placebo use to limited scenarios

• UK regulations allow more flexibility if:

  • The study is scientifically and ethically justified

  • Risk-benefit is acceptable

  • Participants are informed during consent

For manufacturers: Trial design decisions—especially comparator choice—must be carefully justified and documented, balancing ethical expectations with regulatory flexibility.

2. Urgent safety measures

• UK regulations allow immediate implementation without prior ethics approval in urgent cases

• This may conflict with the Declaration’s requirement for prior ethics review

Impact: Manufacturers need clear SOPs for safety events, ensuring:

• Rapid action when required

• Proper notification to authorities and ethics committees

• Full documentation of decisions

3. Post-trial access

• The Declaration expects continued access to beneficial treatments post-trial

• UK law does not mandate this

Consideration: While not legally required, manufacturers may need to address this in ethical justifications, trial planning, and stakeholder expectations.

MHRA’s position: Law takes priority

The MHRA clarifies that:

• Sponsors should aim to comply with both frameworks

• Where conflicts arise, UK law must take precedence

• Any deviation from the Declaration should be clearly justified and documented

What this means for manufacturers

This guidance does not introduce entirely new obligations, but it raises the bar on transparency and justification. Manufacturers should:

• Review clinical trial protocols for alignment with Helsinki principles

• Strengthen documentation and rationale for design decisions

• Ensure internal processes address ethical-regulatory conflicts

• Maintain clear oversight of delegated activities

Read the full document below.